Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions

Ovarian Cancer

Interventions

DRUG

Fluzoparib Capsules

Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily

DRUG

Apatinib Mesylate Tablets

Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)

All Listed Sponsors

lead

The First Affiliated Hospital of Xiamen University

OTHER

NCT06188455 - Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter